217 related articles for article (PubMed ID: 25005770)
1. Effects of tumor necrosis factor inhibitor on serum level of HLA-B27 and PDCD-1 in patients with ankylosing spondylitis.
Chen X; Zhou X; Li X; Tang J; Hu X; Wang J; Xu C
Cell Biochem Biophys; 2014 Nov; 70(2):1453-7. PubMed ID: 25005770
[TBL] [Abstract][Full Text] [Related]
2. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of Toll-like receptor 4 in peripheral blood leucocytes and serum levels of some cytokines in patients with ankylosing spondylitis.
Yang ZX; Liang Y; Zhu Y; Li C; Zhang LZ; Zeng XM; Zhong RQ
Clin Exp Immunol; 2007 Jul; 149(1):48-55. PubMed ID: 17459079
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
5. Relation of HLA-B27, tumor necrosis factor-α promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis -- a comprehensive genotype-phenotype analysis from an observational cohort.
Poddubnyy DA; Märker-Hermann E; Kaluza-Schilling W; Zeidler H; Braun J; Listing J; Sieper J; Rudwaleit M
J Rheumatol; 2011 Nov; 38(11):2436-41. PubMed ID: 21885496
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.
Nossent JC; Sagen-Johnsen S; Bakland G
J Rheumatol; 2014 Aug; 41(8):1675-82. PubMed ID: 25028373
[TBL] [Abstract][Full Text] [Related]
7. HLA-B27 subtypes and tumor necrosis factor alpha promoter region polymorphism in Iranian patients with ankylosing spondylitis.
Nicknam MH; Mahmoudi M; Amirzargar AA; Jamshidi AR; Rezaei N; Nikbin B
Eur Cytokine Netw; 2009 Mar; 20(1):17-20. PubMed ID: 19318316
[TBL] [Abstract][Full Text] [Related]
8. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
[TBL] [Abstract][Full Text] [Related]
9. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
[TBL] [Abstract][Full Text] [Related]
10. Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.
Chen CH; Liao HT; Chen HA; Liu CH; Liang TH; Wang CT; Tsai CY; Chou CT
Rheumatology (Oxford); 2010 Feb; 49(2):264-70. PubMed ID: 20008091
[TBL] [Abstract][Full Text] [Related]
11. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
[TBL] [Abstract][Full Text] [Related]
13. Association of different tumor necrosis factor alpha promoter allele frequencies with ankylosing spondylitis in HLA-B27 positive individuals.
Höhler T; Schäper T; Schneider PM; Meyer zum Büschenfelde KH; Märker-Hermann E
Arthritis Rheum; 1998 Aug; 41(8):1489-92. PubMed ID: 9704649
[TBL] [Abstract][Full Text] [Related]
14. Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis.
Caso F; Costa L; Del Puente A; Rigante D; Selmi C; Fabbroni M; Scarpa R; Galeazzi M; Frediani B; Cantarini L
Clin Exp Rheumatol; 2015; 33(3):411-3. PubMed ID: 25962691
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of etanercept for treating ankylosing spondylitis].
Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
[TBL] [Abstract][Full Text] [Related]
16. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
Rudwaleit M; Listing J; Brandt J; Braun J; Sieper J
Ann Rheum Dis; 2004 Jun; 63(6):665-70. PubMed ID: 15037444
[TBL] [Abstract][Full Text] [Related]
17. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.
Syngle A; Vohra K; Sharma A; Kaur L
Clin Rheumatol; 2010 Jul; 29(7):763-70. PubMed ID: 20204669
[TBL] [Abstract][Full Text] [Related]
18. Quantitative measurement of HLA-B27 mRNA in patients with ankylosing spondylitis-- correlation with clinical activity.
Liu SQ; Yu HC; Gong YZ; Lai NS
J Rheumatol; 2006 Jun; 33(6):1128-32. PubMed ID: 16755659
[TBL] [Abstract][Full Text] [Related]
19. TNF-238A promoter polymorphism contributes to susceptibility to ankylosing spondylitis in HLA-B27 negative patients.
González S; Torre-Alonso JC; Martínez-Borra J; Fernández Sánchez JA; López-Vazquez A; Rodríguez Pérez A; López-Larrea C
J Rheumatol; 2001 Jun; 28(6):1288-93. PubMed ID: 11409121
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.
Wendling D; Cedoz JP; Racadot E
Joint Bone Spine; 2008 Oct; 75(5):559-62. PubMed ID: 18674944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
